





Item 8.01 Other Events.

VistaGen Therapeutics, Inc. (the “Company”) today announced that the U.S. Food and Drug Administration has authorized the Company to proceed, under its Investigational New Drug application, with its planned Phase 2 clinical study of AV-101 as a new generation oral treatment for major depressive disorder. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1, and is incorporated herein by reference.

Item 9.01 Exhibits.

See Exhibit Index.



Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

VistaGen Therapeutics, Inc.

Date: October 26, 2017 By: /s/ Shawn K. Singh  
Shawn K. Singh  
Chief Executive Officer



EXHIBIT INDEX

Exhibit Number    Description

99.1                    Press release issued by VistaGen Therapeutics Inc., dated October 26, 2017.